川崎病诊断、治疗与长期管理:美国心脏协会科学声明
美国心脏协会召集多学科专家组修订川崎病指南,系统评价证据与临床实践意见,更新诊断、急性期治疗和长期管理推荐。声明强调及时诊断,提出经典临床标准不完整时的补充诊断算法,指出静脉注射免疫球蛋白是初始治疗基石,约10%至20%患者无反应并给出追加治疗推荐,长期管理按冠状动脉最大内径Z评分分层,动脉瘤患者需终身不间断心脏科随访。
要点
- 及时诊断至关重要,更新算法定义补充信息以助经典临床标准不完整时的诊断。
- 静脉注射免疫球蛋白是初始治疗基石,约10%至20%患者无反应并需追加治疗。
- 长期管理按冠状动脉最大内径Z评分分层,动脉瘤患者需终身不间断心脏科随访。
核心结论
- 这些推荐为诊断和管理川崎病的医疗提供者提供更新且最佳证据的指导,但临床决策应个体化至具体患者情况。
研究设计与样本
- 为修订先前美国心脏协会指南,召集多学科专家写作组审查和评价现有证据及基于实践的意見,并提供诊断、急性病治疗和长期管理的更新推荐。
主要发现
- 川崎病是儿童急性血管炎,未治疗病例中约25%导致冠状动脉瘤,是发达国家儿童获得性心脏病的主要原因。
- 病因仍未知,讨论部分强调流行病学、遗传学、发病机制、病理学、自然史和长期结局的新见解。
- 约10%至20%的患者对初始静脉注射免疫球蛋白无反应,并提供了追加治疗的推荐。
- 对演变中的冠状动脉异常需仔细初始管理, necessitating increased frequency of assessments and escalation of thromboprophylaxis.
关键数值与推荐
- 长期管理风险分层主要基于最大冠状动脉管腔内径,以Z评分标准化,并校准至过去和当前受累情况。
- 动脉瘤患者需要终身且不间断的心脏科随访。
临床怎么用
- 及时诊断至关重要,更新算法定义补充信息以助经典临床标准不完整时的诊断。
- 静脉注射免疫球蛋白是初始治疗基石,约10%至20%患者无反应并需追加治疗。
- 长期管理按冠状动脉最大内径Z评分分层,动脉瘤患者需终身不间断心脏科随访。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Kawasaki disease is an acute vasculitis of childhood that leads to coronary artery aneurysms in ≈25% of untreated cases. It has been reported worldwide and is the leading cause of acquired heart disease in children in developed countries. METHODS AND RESULTS: To revise the previous American Heart Association guidelines, a multidisciplinary writing group of experts was convened to review and appraise available evidence and practice-based opinion, as well as to provide updated recommendations for diagnosis, treatment of the acute illness, and long-term management. Although the cause remains unknown, discussion sections highlight new insights into the epidemiology, genetics, pathogenesis, pathology, natural history, and long-term outcomes. Prompt diagnosis is essential, and an updated algorithm defines supplemental information to be used to assist the diagnosis when classic clinical criteria are incomplete. Although intravenous immune globulin is the mainstay of initial treatment, the role for additional primary therapy in selected patients is discussed. Approximately 10% to 20% of patients do not respond to initial intravenous immune globulin, and recommendations for additional therapies are provided. Careful initial management of evolving coronary artery abnormalities is essential, necessitating an increased frequency of assessments and escalation of thromboprophylaxis. Risk stratification for long-term management is based primarily on maximal coronary artery luminal dimensions, normalized as Z scores, and is calibrated to both past and current involvement. Patients with aneurysms require life-long and uninterrupted cardiology follow-up. CONCLUSIONS: These recommendations provide updated and best evidence-based guidance to healthcare providers who diagnose and manage Kawasaki disease, but clinical decision making should be individualized to specific patient circumstances.
引用
- McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017. PMID: 28356445. doi:10.1161/CIR.0000000000000484
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。